SUTRO BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
SUTRO BIOPHARMA, INC. (STRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-23
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 1.00%, a 37.50% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.60%, a 37.25% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-03-31 was 2.55%, a 6.59% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-03-31 was 2.73%.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.20%, a 10.64% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.70%, a 0.00% change from fiscal 2023.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.70%, a 11.90% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.20%, a 223.08% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 4.20% 10-K · filed 2026-03-23 | |||||||
| 2024-12-31 | 4.70% 10-K · filed 2026-03-23 | |||||||
| 2023-12-31 | 4.70% 10-K · filed 2025-03-13 | |||||||
| 2022-12-31 | 4.20% 10-K · filed 2025-03-13 | |||||||
| 2022-06-30 | 3.40% 10-Q · filed 2022-08-08 | |||||||
| 2021-12-31 | 1.30% 10-K · filed 2024-03-25 | |||||||
| 2021-09-30 | 1.10% 10-Q · filed 2021-11-10 | |||||||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-08 | |||||||
| 2021-03-31 | 1.00% 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | 1.60% 10-K · filed 2023-03-30 | |||||||
| 2020-09-30 | 1.60% 10-Q · filed 2021-11-10 | 1.62% 10-Q · filed 2020-11-05 | ||||||
| 2020-06-30 | 1.60% 10-Q · filed 2021-08-09 | 1.62% 10-Q · filed 2020-08-06 | ||||||
| 2020-03-31 | 1.60% 10-Q · filed 2021-05-07 | 1.62% 10-Q · filed 2020-05-11 | ||||||
| 2019-12-31 | 2.60% 10-K · filed 2022-02-28 | 1.42% 10-K · filed 2020-03-16 | ||||||
| 2019-09-30 | 2.55% 10-Q · filed 2020-11-05 | |||||||
| 2019-06-30 | 2.55% 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | 2.55% 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | 3.10% 10-K · filed 2021-03-18 | 3.11% 10-K · filed 2019-04-01 | ||||||
| 2018-09-30 | 2.97% 10-Q · filed 2019-11-08 | |||||||
| 2018-06-30 | 2.73% 10-Q · filed 2019-08-14 | |||||||
| 2018-03-31 | 2.73% 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | 2.18% 10-K · filed 2020-03-16 | |||||||
| 2017-09-30 | 2.10% 10-Q · filed 2018-11-14 | |||||||
| 2016-12-31 | 2.09% 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |